Therapeutic area intelligence for Alcohol Use Disorder with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Eli Lilly →

Assets

Mazdutide →

NIAAA →

Tirzepatide →

Recent signals(4)

CompetitiveJune 27, 2026

Eli Lilly's Mazdutide Shows Promise in Alcohol Use Disorder Study

Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder.

ClinicalJune 26, 2026

NIAAA Launches Study on Addictions Neuroclinical Assessment for Alcohol Use Disorder

The NIAAA is testing a new assessment tool called the Addictions Neuroclinical Assessment (ANA) to better understand alcohol use disorder.

ClinicalJune 22, 2026

Tirzepatide Trial for Metabolic Alcohol-Associated Liver Disease in AUD Patients

A clinical trial is underway to evaluate the efficacy of Tirzepatide in patients with Alcohol Use Disorder and MetALD.

ClinicalJune 22, 2026

Study on Alcohol's Impact on PDE4B Imaging in Healthy Adults

A study is investigating how alcohol affects PDE4B activity in the brain using PET imaging.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Alcohol Use Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.